



# XIX International Symposium on Amyloidosis



May 26-30, 2024  
Mayo Civic Center, Rochester, MN

*This is the conference you don't want to miss!*

[cveducation.mayo.edu/amyloid](https://cveducation.mayo.edu/amyloid)

Program Directors:  
Drs. Angela Dispenzieri, Morie Gertz, Martha Grogan - Mayo Clinic  
Dr. Stefan Schönland - Heidelberg University Hospital, Germany, ISA President 2022-2024

Dear Colleagues,

Welcome to ISA 2024. Please note the following:

1. ISA officially begins on Sunday May 26th at 4:30 P.M.
2. ISA subcommittee meetings will be conducted by invitation only on May 26th before the official opening of the ISA meeting.
3. IKMG which is in part sponsored by but separate from ISA will be conducted on May 25th to early morning May 26th.

Best regards,

Angela, Morie, Martha, and Stefan

# Full Program

General Session – Mayo Civic Center, 2<sup>nd</sup> Floor Ballroom

Exhibits – Mayo Civic Center, 1<sup>st</sup> Floor Exhibit Hall

Posters – Mayo Civic Center, 1<sup>st</sup> Floor Auditorium

## Sunday, May 26

Time		Presentation	Speakers
<b>1:00-6:15</b>		<b>Registration Opens</b>	
4:30-4:45		Welcome and Meeting Overview	<i>S. Schönland</i> <i>A. Dispenzieri</i> <i>M. Grogan</i>
4:45-5:00		ISA Merlini Award Introduction	<i>G. Merlini</i>
5:00-5:45		ISA Merlini Award Acceptance	<i>M. Saraiva</i>
5:45-6:00		Skinner Awards	<i>V. Sanchorawala</i>
6:00-6:15		Amyloidosis Foundation Travel Awards	<i>Amyloidosis Foundation</i>
6:15		Adjourn	
<b>6:30-8:30 PM</b>		<b>Welcome Reception and Mayo Tours: Gonda &amp; Mayo Buildings</b>	

## Monday, May 27

Time	Poster Location (Abstract ID)	Presentation	Speakers
<b>6:30-7:30</b>		<b>Registration/Exhibits/Posters/Breakfast</b>	
7:30-8:30		Amyloid Primer: Understanding Other Subspecialties 1. Neurology for Non-neurologists, Numbness, Needles, and NIS 2. Cardiology: Beyond EF and Wall Thickness 3. Hematology: What do all the Acronyms Mean?	<i>S. Kumar (moderator)</i> <i>C. Karam</i> <i>I. Chang</i> <i>R. Warsame</i>
8:30-9:00		The History of Amyloid and Patient Perspective	<i>M. Gertz</i> <i>M. Keilson</i>
<b>9:00-10:00 AM</b>		<b>Diagnosis of Amyloid Session / Oral Abstracts</b> Moderators: <i>S. Schönland</i> , E. McPhail, I. Conceicao	
9:00-9:15		Plenary Lecture: Challenges in the Diagnosis of Amyloid in 2024	<i>S. Schönland</i>
9:15-9:25	OA1 (#496)	A Feasibility Study into Computer Vision Quantification of Cardiac Amyloid Burden in Endomyocardial Biopsies	<i>T. Kourelis</i>
9:25-9:35	OA2 (#99)	AmyLite™ Assay Quantifies Kinetically Unstable Circulating Amyloidogenic Lambda FLC – Diagnostic and Prognostic Implications for Lambda AL Amyloidosis	<i>X. Jiang</i>
9:35-9:45	OA3 (#420)	Lumbar Spinal Stenosis (LSS) and Carpal Tunnel Syndrome (CTS) as Surrogates for Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	<i>L. DeMichieli</i>
9:45-9:55	OA4 (#564)	Screening for Amyloidosis at the Time of Carpal Tunnel Release Surgery in Real World Practice is a Successful Strategy at Diagnosing Early Cardiac Amyloidosis	<i>M. Hanna</i>
9:55-10:00		<b>Questions and Answers</b>	
<b>10:00-10:30 AM</b>		<b>Refreshment Break: Visit Exhibits and Posters</b>	
<b>10:30-11:45 AM</b>		<b>AL Basic Science / Oral Abstracts</b> Moderators: C. Sirac, J. Wall, T. Kourelis	
10:30-10:45		Plenary Lecture: Basic Mechanism of Disease in AL: Unanswered Questions	<i>C. Sirac</i>

10:45-10:55	OA5 (#464)	Bone Marrow-free Sequencing of M Protein Genes: A Liquid Biopsy Approach in Monoclonal Gammopathies	<i>A. Nevone</i>
10:55-11:05	OA6 (#253)	Characterization of the Peptide-Antibody Fusion, AT-02 – Studies to Support its Use as an Immunotherapy in Patients with Amyloidosis	<i>J. Wall</i>
11:05- 11:15	OA7 (#38)	Helical Superstructures Between Amyloid and Collagen VI in Heart-derived Fibrils from a Patient with Light Chain Amyloidosis	<i>S. Ricagno</i>
11:15-11:25	OA8 (#181)	Patient Derived AL Amyloid Induces Cellular Toxicity in Macrophages, Hepatocytes, and Cardiomyocytes Upon Cellular Engulfment of Amyloid Material	<i>J. Jackson</i>
11:25-11:35	OA9 (#333)	Single-cell, Spatial Analysis of the Renal AL Immunome Supports a T-cell Mediated Tissue Toxicity Mechanism	<i>C. Charalampous</i>
11:35-11:45		<b>Questions and Answers</b>	
11:45-12:15 PM		<b>Lunch</b>	
<b>12:15-1:30 PM</b>		<b>Satellite Sessions (30 min each)</b>	
12:15-12:45		Prothena Industry Theater: Pioneering the Next Era in Treating Amyloidosis	<i>H. Garren, J. Khouri, A. D'Souza</i>
1:00-1:30		Pfizer Industry Theater: Leading with Heart: Enabling Earlier Diagnosis and Intervention in Patients with ATTR-CM	<i>S. Dorbala, P. Garcia-Pavia</i>
<b>1:30-2:45 PM</b>		<b>AL Diagnosis / Prognosis and Treatment / Oral abstracts</b> Moderators: A. Wechalekar, P. Milani, F. Buadi	
1:30-1:45		Plenary Lecture: Limitations of Current Staging Systems for AL <b>Pre-recorded</b>	<i>A. Wechalekar</i>
1:45-1:55	OA10 (#466)	A Phase II Study of Daratumumab and Pomalidomide in Previously Treated Patients with AL Amyloidosis	<i>P. Milani</i>
1:55-2:05	OA11 (#209)	Clinical Factors Associated with Early Sudden Unexpected Death in Systemic AL Amyloidosis: Insights from 138 Cases	<i>A. Staron</i>
2:05-2:15	OA12 (#267)	An ECG-Echo Risk Score for Systemic Light Chain Amyloidosis	<i>A. Hari</i>
2:15-2:25	OA13 (#529)	Daratumumab-Based Front-line Therapy Improves Treatment Response and Survival in Patients with Immunoglobulin Light chain (AL) Amyloidosis: The Mayo Clinic Experience	<i>B. Yohannan</i>
2:25-2:35	OA14 (#185)	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network	<i>E. Kastritis</i>
2:35-2:45		<b>Questions and Answers</b>	
<b>2:45-3:45 PM</b>		<b>Refreshment Break / Visit Exhibits &amp; Moderated Poster Sessions</b> Moderators: S. Schönland, C. Sirac, P. Milani, P. Scheinberg, J. Wixner	
<b>3:45-5:00 PM</b>		<b>AL Prognosis and Treatment / Oral abstracts</b> Moderators: E. Kastritis, H. Landau, U. Hegenbart	
3:45-4:00		Plenary Lecture: Unmet Needs in Treatment of AL	<i>E. Kastritis</i>
4:00-4:10	OA15 (#273)	Ethnicity in AL Amyloidosis Shows Underestimation of Disease Risks by Biomarker-based Staging for Ethnic Minorities Patients in Systemic AL Amyloidosis	<i>J. Khwaja</i>
4:10-4:20	OA16 (#501)	Outcomes of Patients with AL Amyloidosis and End-stage Renal Disease After Initiation of Therapy	<i>E. Kastritis</i>
4:20-4:30	OA17 (#264)	Peripheral Neuropathy in AL Amyloidosis: Clinical Presentations and Outcomes of Current Therapies	<i>P. Chompoopong</i>
4:30-4:40	OA18 (#235)	Plasma Cell Characteristics Predict Benefit from Intensified Therapy in AL Amyloidosis	<i>M. Steinhardt</i>
4:40-4:50	OA19 (#475)	Proposed Hematologic Progression Criterion in Patients with AL Amyloidosis	<i>G. Palladini</i>
4:50-5:00		<b>Questions and Answers</b>	
<b>5:30-10:00 PM</b>		<b>Reception &amp; Evening Sessions: Gonda, Mayo Buildings, Annenberg Plaza</b>	

6:00-7:00		<b>Gonda Lobby:</b> Meet the Experts: Cases with the Aces <i>Speakers: V. Sanchorawala, M. Maurer, V. Jimenez Zepeda, M. Mauermann, P. Garcia-Pavia, N. Nativi Nicolau</i>	<b>Mayo Tours</b>
7:00-8:00		<b>Gonda Lobby:</b> Meet the Experts: Mass Spectrometry and Special Protein Laboratories Virtual Lab Tour and Q & A / <i>Speakers: E. McPhail, S. Dasari, D. Murray</i>	<b>Mayo Building Lobby:</b> Meet the Experts: Social Networking <i>Speakers: A. Dispenzieri, P. James Dyck, M. Gertz, J. Gillmore, M. Maurer, J. Wall</i>
7:00-10:00		Band: The Soul Train; Annenberg Plaza	<b>Mayo Tours</b>

## Tuesday, May 28

Time	Poster Location (Abstract ID)	Presentation	Speakers
<b>6:30-7:30 AM</b>		<b>Breakfast</b>	
7:30-8:30		Supportive Care for Amyloidosis: Multidisciplinary Approach 1. Patient Perspective: What Matters Most? 2. Managing Hypotension and Neuropathy 3. Top Ten Tips for Treating Amyloid Heart Failure 4. Calming the Gut 5. Panel Discussion	<i>S. Sidana (moderator)</i> <i>I. Lousada</i> <i>A. Carroll</i> <i>J. Rosenthal</i> <i>J. Clarke</i>
<b>8:30-10:00 AM</b>		<b>Imaging of Amyloid / Oral Abstracts</b> Moderators: S. Dorbala, M. Fontana, P. Soman	
8:30-8:45		Plenary Lecture: Molecular Imaging to Unravel the Pathophysiology of Cardiac Amyloidosis	<i>S. Dorbala</i>
8:45-8:55	OB1 (#296)	Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers	<i>E. Martin</i>
8:55-9:05	OB2 (#444)	Diagnostic Performance of [18F]-Florbetaben PET for the Detection of Cardiac Involvement in AL Amyloidosis: First Results of the MoRBIDA Trial	<i>P. Milani</i>
9:05-9:15	OB3 (#287)	First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis	<i>M. Kim</i>
9:15-9:25	OB4 (#401)	Comparative Analysis of Clinical and Echocardiographic Variations in Cardiac Amyloidosis Subtypes	<i>F. Massad</i>
9:25-9:35	OB5 (#405)	The Limitations of 99mTc-DPD Scintigraphy in Tracking Treatment Response in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	<i>J. Gillmore</i>
9:35-9:45	OB6 (#383)	Utility of 18F-PET Scintigraphy to Detect Inflammatory Light Chain Proteotoxicity in Cardiac AL Amyloidosis	<i>J. Khwaja</i>
<b>9:45-10:00</b>		<b>Questions and Answers</b>	
<b>10:00-10:30 AM</b>		<b>Refreshment Break: Visit Exhibits and Posters</b>	
<b>10:30-11:45 AM</b>		<b>MGCS / Other Cardiomyopathies / Oral Abstracts</b> Moderators: A. Jaccard, A. Masri, P. Scheinberg	
10:30-10:45		Plenary Lecture: Mimickers of Cardiac Amyloidosis: Do not get fooled!	<i>A. Masri</i>
10:45-10:55	OB7 (#532)	Prevalence of Amyloid Deposition in Patients Undergoing Surgical Myectomy for Presumed Hypertrophic Cardiomyopathy	<i>D. Katzianer</i>
10:55-11:05	OB8 (#18)	Prevalence of Transthyretin Amyloid Cardiomyopathy in Patients with Hypertrophic Cardiomyopathy: Final Analysis of the TTRACK Study	<i>T. Damy</i>
11:05-11:20		Plenary Lecture: When is Monoclonal Gammopathy Clinically Significant	<i>A. Jaccard</i>
11:20-11:30	OB9 (#327)	Epidemiology and Clinical Characteristics of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in a Diverse Population	<i>E. Granina</i>
11:30-11:40	OB10 (#313)	Light-Chain MGUS Defined as per the Revised Definition of the ISTOPMM Study: Experience from the University of Calgary MGUS Clinic	<i>V. Jimenez Zepeda</i>
<b>11:40-11:45</b>		<b>Questions and Answers</b>	
<b>11:45-12:15 PM</b>		<b>Lunch</b>	
<b>12:15-1:30 PM</b>		<b>Satellite Session</b>	

12:15-1:30		Controversies in the Management of Cardiac Amyloidosis (Sponsored by an unrestricted grant from BridgeBio) 1. Digoxin: Wrongfully Accused? 2. Beta-Blockers: Always Bad? 3. Entresto: Should We Ever Use It? 4. Mineralocorticoids: Yes, No? 5. SGLT2i for All? 6. Watchman: Wait a Minute? 7. Panel Discussion Q & A	<i>T. Damy (moderator)</i> <i>R. Cheng</i> <i>A. Masri</i> <i>M. Lyle</i>
<b>1:30-2:45 PM</b>		<b>Special Topics</b> Moderator: J. Kelly	
1:30-2:00		Plenary Lecture: Alzheimer's: Clinical Lessons Learned	<i>N. Ertekin-Taner</i>
2:00-2:30		Plenary Lecture: Long-Term TTR Suppression: Is There a Downside?	<i>J. Buxbaum</i>
2:30-2:45		Panel Discussion	
<b>2:45-3:45 PM</b>	Location: Poster Viewing Area	<b>Refreshment Break / Visit Exhibits &amp; Moderated Poster Sessions</b> Moderators: S. Dorbala, P. Garcia-Pavia, P. Mollee, R. Ruberg	
<b>3:45-5:00 PM</b>		<b>ATTR Basic Science / Oral Abstracts</b> Moderators: L. Saelices Gomez, M. Ueda, H. Koike	
3:45-4:00		Plenary Lecture: Gaps in our Understanding of the Pathophysiology of ATTR	<i>L. Saelices Gomez</i>
4:00-4:10	OB11 (#324)	Deciphering the Pathogenesis of Transthyretin Cardiac Amyloidosis in a Humanized Mouse Model	<i>X. Wu</i>
4:10-4:20	OB12 (#104)	NMR Reveals Structural and Dynamics Changes of Transthyretin that were Hidden in X-ray Studies	<i>A. Corazza</i>
4:20-4:30	OB13 (#449)	NMR study of Transthyretin Binding by Monovalent and Bivalent Stabilizers in Human Serum	<i>A. Corazza</i>
4:30-4:40	OB14 (#451)	Rac1 Activation Triggers Axonal Cytoskeleton Dysfunction in Transthyretin Amyloid Polyneuropathy	<i>M. Liz</i>
4:40-4:50	OB15 (#270)	Whole Tissue Proteomic Analyses of Cardiac ATTR and AL Unveil Mechanisms of Tissue Damage.	<i>T. Kourelis</i>
4:50-5:00	OB16 (#339)	What the Structures of Amyloids Teach us About Amyloid Pathology	<i>F. Rousseau</i>
<b>5:00-5:15</b>		<b>Questions and Answers</b>	
<b>5:15-9:00 PM</b>		<b>Reception &amp; Evening Sessions: Mayo Civic Center, Rochester Art Center, Mayowood</b>	
5:15-7:00		Mayo Civic Center Reception by the River on the Patio. Rochester Art Center <i>Celebrities</i> by Pat York (Entryway corridor & grand lobby) View prior to and during reception	
6:30-9:30		<b>By invitation only:</b> Faculty depart Mayo Civic Center Entrance for Faculty Reception & Dinner at Historic Mayowood.	

## Wednesday, May 29

Time	Poster Location (Abstract ID)	Presentation	Speakers
<b>6:30-7:30 AM</b>		<b>Breakfast</b>	
7:30-8:30		Reducing Health Care Disparities in Amyloidosis <ol style="list-style-type: none"> <li>1. Raising Awareness: the scope of the problem in ATTR</li> <li>2. Raising Awareness: the scope of the problem in AL</li> <li>3. Hereditary ATTR: Challenges of screening and follow-up (including carriers)</li> <li>4. Diagnostics in an underserved population: Real world experience</li> <li>5. Call to action: Networking strategies to promote health care equity.</li> <li>6. Panel Discussion and Audience Interaction</li> </ol>	<i>A. D'Souza (Co-Chair)</i> <i>K. Alexander (Co-Chair)</i> <i>J. Grodin</i> <i>S. Malhotra</i>
<b>8:30-10:00 AM</b>		<b>ATTR Diagnosis / Oral Abstracts</b> Moderators: J. Gillmore, Y. Sekijima	
8:30-8:45		Plenary Lecture: Prognosis of ATTR in the Treatment Era	<i>J. Gillmore</i>
8:45-8:55	OC1 (#175)	Surprising Findings of Transthyretin in Stenotic Aortic Valves	<i>U. Thelander</i>
8:55-9:05	OC2 (#531)	Serum Neurofilament Light Chain Levels Show Promise as a Biomarker for Early Detection and Diagnosis of ATTRv Amyloidosis: A Meta-analysis	<i>K. Appiah-Kubi</i>
9:05-9:15	OC3 (#555)	Clinical Laboratory and Electrocardiogram Models to Screen for Transthyretin Cardiac Amyloidosis	<i>S. Dasari</i>
9:15-9:25	OC4 (#330)	Analysis of the Intestinal Microbiome in Patients with Transthyretin Amyloidosis with and without Cardiac Involvement and Its Correlation with Echocardiographic Parameters and Biomarkers	<i>J. Henrique Rissato</i>
9:25-9:35	OC5 (#115)	High Sensitivity Cardiac Troponin I for Risk Stratification in Wild-type Transthyretin Amyloid Cardiomyopathy	<i>L. DeMichieli</i>
9:35-9:45	OC6 (#257)	Impact of SGLT2 Inhibitors on the Incidence of Cardiac Arrhythmias and Overall Outcomes in Transthyretin Cardiac Amyloidosis	<i>S. Byer</i>
<b>9:45-10:00</b>		<b>Questions and Answers</b>	
<b>10:00-10:30 AM</b>		<b>Refreshment Break: Visit Exhibits and Posters</b>	
<b>10:30-11:45 AM</b>		<b>ATTR Prognosis &amp; Treatment / Oral Abstracts</b> Moderators: M. Hanna, M. Waddington Cruz, J. Wixner	
10:30-10:45		Plenary Lecture: Treatment of ATTR, Is there a Role for Dual/Triple Therapy?	<i>M. Hanna</i>
10:45-10:55	OC7 (#281)	Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Results from the ATTRIBUTE-CM Clinical Trial	<i>K. Alexander</i>
10:55-11:05	OC8 (#136)	RV-PA Uncoupling is a Strong Predictor of Mortality in Transthyretin Amyloid Cardiomyopathy	<i>S. Schwarting</i>
11:05-11:15	OC9 (#261)	The Impact of an Active Ascertainment Approach on Differences in Echocardiographic Phenotypes for Women Diagnosed with Transthyretin Cardiac Amyloidosis: The SCAN-MP Study	<i>D. Smiley</i>
11:15-11:25	OC10 (#282)	Treatment-related Early Increase in Serum TTR is Associated with Lower Cardiovascular Hospitalization in ATTR-CM: Insights from ATTRIBUTE-CM	<i>M. Davis</i>
11:25-11:35	OC11 (#387)	Clinical Impact of Beta-blocker Withdrawal in Transthyretin Amyloid Cardiomyopathy	<i>N. Mora Aystarán</i>

<b>11:35-11:45</b>		<b>Questions and Answers</b>	
<b>11:45-12:15 PM</b>		<b>Lunch</b>	
<b>12:15-1:30 PM</b>		<b>Satellite Session</b>	
12:15-1:30		AstraZeneca Industry Theater – Don't be NERVEous: Addressing Polyneuropathy in hATTR.	<i>N. Sarswat, M. Alejandra Gonzalez-Duarte Briseno, B. Sperry, A. Peltier</i>
		<b>SIMULTANEOUS SESSIONS</b>	
<b>1:30-2:45 PM</b>	2 <sup>nd</sup> Floor Ballroom	<b>Other Amyloids, Clinical / Oral Abstracts</b> Moderators: L. Obici, H. Lachmann	
1:30-1:45		Plenary Lecture: Beyond AI and ATTR: Clinical Features of "Other" Types of Systemic Amyloidosis	<i>L. Obici</i>
1:45-1:55	OC12 (#193)	Antisense Oligonucleotide Therapy for Familial AA amyloidosis, A N of 1 trial	<i>N. Leung</i>
1:55-2:05	OC13 (#169)	Autosomal Dominant ApoA4 Mutations Present as Tubulointerstitial Kidney Disease with Medullary Amyloidosis	<i>A. Hnizda</i>
2:05-2:15	OC14 (#495)	Biomarker-based Renal Response and Progression Criteria in AA Amyloidosis: Results from the Testing Cohort of the Pavia-Heidelberg Study	<i>M. Basset</i>
2:15-2:25	OC15 (#34)	Inflammatory Diseases Underlying AA Amyloidosis: Analysis of 952 Patients Seen at a Single Reference Centre over 34 years	<i>H. Lachmann</i>
2:25-2:35	OC16 (#408)	The Fibrillogenic ApoAIV Signal Sequence is an Excellent Proteomic Marker for Diagnosing AApoAIV Amyloidosis	<i>E. McPhail</i>
<b>2:35-2:45</b>		<b>Questions and Answers</b>	
<b>1:30-2:45 PM</b>	1 <sup>st</sup> Floor Presentation Hall	<b>ISA Frontline Bootcamp / Part 1: Multi-disciplinary Management of Amyloidosis</b>	
1:30-1:40		How we Explain Amyloid to our Patients	<i>L. Hwa; J. Grazzini Frantz</i>
1:40-1:45		Amyloidosis Support Group	<i>M. Finkel</i>
1:45-1:50		Amyloid Research Consortium	<i>I. Lousada</i>
1:50-1:55		MacKenzie's Mission	<i>D. Boedicker</i>
1:55-2:35		Managing Symptoms	<i>L. Hwa; J. Grazzini Frantz</i>
<b>2:35-2:45</b>		<b>Questions and Answers</b>	
<b>2:45-3:45 PM</b>	Location: Poster Viewing Area	<b>Refreshment Break / Visit Exhibits &amp; Moderated Poster Sessions</b> Moderators: O. Abou Ezzedine, U. Hegenbart, D. Judge, V. Sanchorawala, P. Soman, T. Damy	<i>Location: Poster viewing area</i>
		<b>SIMULTANEOUS SESSIONS</b>	
<b>3:45-5:00 PM</b>	2 <sup>nd</sup> Floor Main Ballroom	<b>Other Amyloids-Basic Science / Oral Abstracts</b> Moderators: O. Gursky, G. Westermark, M. Ramirez-Alvarado	
3:45-4:00		Plenary Lecture: Role of Amyloid Signature Proteins in Modulation of Amyloid Formation	<i>O. Gursky</i>
4:00-4:10	OC17 (#27)	Amyloid-collagen Fibrils as Potential Templates for Pathologic Biomineralization in Calcific Aortic Valve Disease	<i>O. Gursky</i>
4:10-4:20	OC18 (#155)	Interactions of Variants of Human Apolipoprotein A-I with Biopolymeric Model Matrices. Effect of Collagen and Heparin	<i>M. Alejandra Tricerrì</i>
4:20-4:30	OC19 (#350)	Investigating Cross-seeding Interactions of Functional Amyloids	<i>R. Price</i>
4:30-4:40	OC20 (#378)	Local Amyloid Motifs Mediate Tau Polymorphism and Cellular Propagation	<i>N. Louros</i>
4:40-4:50	OC21 (#83)	Implication of Serum Amyloid A and Apolipoprotein E Polymorphism in AA Amyloidosis Secondary to Rheumatoid Arthritis	<i>T. Kuroda</i>
<b>4:50-5:00</b>		<b>Questions and Answers</b>	



<b>3:45-5:00 PM</b>	1 <sup>st</sup> Floor Auditorium	<b>ISA Frontline Bootcamp / Part 2: Multi-disciplinary Management of Amyloidosis</b>	
3:45-3:50		Patients and Families in Shock	<i>L. Hwa; J. Grazzini Frantz</i>
3:50-4:05		Managing Neuro Symptoms	<i>K. Shouman</i>
4:05-4:20		Nuts and Bolts of Money Matters	<i>F. Bryant Esq</i>
4:20-4:35		Genetics	<i>L. Boucher</i>
4:35-4:55		Palliative Care	<i>M. Eick</i>
<b>4:55-5:00</b>		<b>Questions and Answers</b>	
<b>5:00-6:00</b>		<b>Free Time</b>	
<b>6:00-10:00 PM</b>		<b>Evening Reception</b>	
6:00		Buses Departs Mayo Civic Center Entrance for Stone Barn for Dinner & Entertainment. Buses will return between 8:30-10:00	

## Thursday, May 30

Time		Presentation	Speakers
<b>6:30-7:30 AM</b>		<b>Breakfast</b>	
7:30-8:30		<b>Treatment Endpoints for Amyloid Trials – Interactive Workshop</b> The panel will discuss current state and future of amyloid response criteria	<i>A. Dispenzieri (Moderator)</i> <i>E. Muchtar; M. Maurer;</i> <i>A. D’Souza, G. Palladini; D. Judge</i>
<b>8:30-10:00 AM</b>		<b>Challenges in Amyloid</b> Moderators: P. Mollee	
8:30-8:45		Heart Transplant	<i>R. Witteles</i>
8:45-9:00		ICD in Cardiac Amyloid	<i>F. Ruberg</i>
9:00-9:15		Kidney Transplant	<i>N. Leung</i>
9:15-9:30		ASCT for AL: Still a Role?	<i>M. Roussel</i>
9:30-10:00		<b>Questions and Answers / Panel Discussion</b>	
<b>10:00-10:30</b>		<b>Refreshment Break: Visit exhibits and posters</b>	
<b>10:30-11:15 AM</b>		<b>Business meeting for ISA Members</b>	
11:15-11:30		Closing Remarks	<i>A. Dispenzieri, M. Gertz, M. Grogan, S. Schönland, S. Kumar</i>
<b>11:30-12:00 PM</b>		<b>Lunch</b>	

## Thursday, May 30 Patient Sessions

<b>12:00-3:45</b>		<b>Patient Session – Main Ballroom</b>	
12:00-12:20		Welcome and Introductions	<i>AF, ASG, ARC, Mackenzie’s Mission, and Amyloid Alliance/J. Christophe Fidalgo</i>
12:20-12:50		ISA Summary for AL Treatments	<i>A. Dispenzieri</i>
12:50-1:20		ISA Summary for ATTR Treatments	<i>M. Grogan</i>
1:20-1:30		<b>Questions and Answers</b>	
1:30-1:40		ISA Summary for Anti-Fibrils AL	<i>M. Gertz</i>
1:40-1:50		ISA Summary for Anti-Fibrils ATTR	<i>R. Cheng</i>
1:50-2:00		<b>Questions and Answers</b>	
<b>2:00-2:15 PM</b>		<b>Refreshment Break</b>	
2:15-2:45		Insurance/Medicare Considerations	<i>F. Bryant Esq</i>
2:45-2:50		Financial Aid	<i>P. Schmitt, ASG</i>
2:50-3:05		Community Survey	<i>S. Rebello, ARC</i>
3:05-3:30		Update on Clinical Trials	<i>K. Hsu, ARC</i>
3:30-3:45		<b>Questions and Answers</b>	
3:45-4:00		Closing Remarks	

AGENDA for Frontline Boot Camp at ISA – Wednesday, May 29		
1:30-1:40	How we Explain Amyloid to our Patients	L. Hwa J. Grazzini Frantz
1:40-1:45	Amyloidosis Support Group	M. Finkel
1:45-1:50	Amyloid Research Consortium	I. Lousada
1:50-1:55	MacKenzie's Mission	D. Boedicker
1:55-2:35	Managing Symptoms	L. Hwa J. Grazzini Frantz
2:35-2:45 PM	Questions and Answers	
2:45-3:45 PM	Break	
3:45-3:50	Patients and Families in Shock	L. Hwa J. Grazzini Frantz
3:50-4:05	Managing Neuro Symptoms	K. Shouman
4:05-4:20	Nuts and Bolts of Money Matters	F. Bryant Esq
4:20-4:35	Genetics	L. Boucher
4:35-4:55	Palliative Care	M. Eick
4:55-5:00 PM	Questions and Answers	

AGENDA for Patient Meeting at ISA – Thursday, May 30		
11:15 AM	Lunch	
12:00	Welcome and Introductions	AF (Lorie Lawter), ASG (Muriel Finkel), ARC (Isabelle Lousada), Mackenzie's Mission (Deborah Boedicker), and Amyloidosis Alliance (Jean Fidalgo)
12:20	ISA Summary for AL Treatments	Dispenzieri, Grogan, Gertz, Mayo
12:50	ISA Summary for ATTR Treatments	Dispenzieri, Grogan, Gertz, Mayo
1:20 PM	Q & A	
1:30	ISA Summary for Anti-Fibrils AL	Dispenzieri, Grogan, Gertz, Mayo
1:40	ISA Summary for Anti-Fibrils ATTR	Dispenzieri, Grogan, Gertz, Mayo
1:50 PM	Q & A	
2:00 PM	Break	
2:15	Insurance/Medicare Considerations	F. Bryant Esq
2:45	Financial Aid	P. Schmitt, ASG
2:50	Community Survey	S. Rebello, ARC
3:05	Update on Clinical Trials	K. Hsu, ARC
3:30 PM	Q & A	
3:45 PM	Close	